APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anticoagulants

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

Selected research

Market Analysis & Forecast

Global Anticoagulants Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchAnticoagulants Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Anticoagulants Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Anticoagulants Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anticoagulants Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Anticoagulants Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.

North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.

Read the full market overview

Report Includes

This report presents an overview of global market for Anticoagulants, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anticoagulants, also provides the revenue of main regions and countries. Of the upcoming market potential for Anticoagulants, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anticoagulants revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anticoagulants market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anticoagulants revenue, projected growth trends, production technology, application and end-user industry.

Anticoagulants Segment by Company

Sanofi

Bristol-Myers Squibb

Bayer

Johnson & Johnson.

Genentech (Roche)

Boehringer Ingelheim

Lilly

Daiichi Sankyo

Otsuka

AstraZeneca

Pfizer

Aspen

The Medicines Company

Anticoagulants Segment by Type

Platelet Aggregation Inhibitors (PAI)

Low-Molecular-Weight Heparin (LMWH)

Direct Thrombin Inhibitor (DTI)

Direct Factor Xa Inhibitors (DFXa)

Vitamin K antagonists (VKA)

Others

Anticoagulants Segment by Application

VTE

ACS/MI

AF

Others

Anticoagulants Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticoagulants market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anticoagulants and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticoagulants.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anticoagulants in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anticoagulants company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anticoagulants revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anticoagulants Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Platelet Aggregation Inhibitors (PAI) Major Player Table 3. Low-Molecular-Weight Heparin (LMWH) Major Player Table 4. Direct Thrombin Inhibitor (DTI) Major Player Table 5. Direct Factor Xa Inhibitors (DFXa) Major Player Table 6. Vitamin K antagonists (VKA) Major Player Table 7. Others Major Player Table 8. Global Anticoagulants Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. VTE Major Player Table 10. ACS/MI Major Player Table 11. AF Major Player Table 12. Others Major Player Table 13. Anticoagulants Industry Trends Table 14. Anticoagulants Industry Drivers Table 15. Anticoagulants Industry Opportunities and Challenges Table 16. Anticoagulants Industry Restraints Table 17. Global Anticoagulants Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Anticoagulants Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Anticoagulants Market Share by Region (2021-2026) Table 20. Global Anticoagulants Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Anticoagulants Market Share by Region (2027-2032) Table 22. Global Anticoagulants Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Anticoagulants Revenue Market Share by Players (2021-2026) Table 24. Global Anticoagulants Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Anticoagulants Key Players Headquarters & Area Served Table 26. Global Anticoagulants Players, Product Type & Application Table 27. Global Anticoagulants Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Anticoagulants by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Anticoagulants Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Anticoagulants Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Anticoagulants Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Anticoagulants Revenue Market Share by Type (2021-2026) Table 34. Global Anticoagulants Revenue Market Share by Type (2027-2032) Table 35. Global Anticoagulants Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Anticoagulants Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Anticoagulants Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Anticoagulants Revenue Market Share by Application (2021-2026) Table 39. Global Anticoagulants Revenue Market Share by Application (2027-2032) Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sanofi Anticoagulants Product Portfolio Table 44. Sanofi Recent Development Table 45. Bristol-Myers Squibb Company Information Table 46. Bristol-Myers Squibb Business Overview Table 47. Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Bristol-Myers Squibb Anticoagulants Product Portfolio Table 49. Bristol-Myers Squibb Recent Development Table 50. Bayer Company Information Table 51. Bayer Business Overview Table 52. Bayer Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bayer Anticoagulants Product Portfolio Table 54. Bayer Recent Development Table 55. Johnson & Johnson. Company Information Table 56. Johnson & Johnson. Business Overview Table 57. Johnson & Johnson. Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Johnson & Johnson. Anticoagulants Product Portfolio Table 59. Johnson & Johnson. Recent Development Table 60. Genentech (Roche) Company Information Table 61. Genentech (Roche) Business Overview Table 62. Genentech (Roche) Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Genentech (Roche) Anticoagulants Product Portfolio Table 64. Genentech (Roche) Recent Development Table 65. Boehringer Ingelheim Company Information Table 66. Boehringer Ingelheim Business Overview Table 67. Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Boehringer Ingelheim Anticoagulants Product Portfolio Table 69. Boehringer Ingelheim Recent Development Table 70. Lilly Company Information Table 71. Lilly Business Overview Table 72. Lilly Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Lilly Anticoagulants Product Portfolio Table 74. Lilly Recent Development Table 75. Daiichi Sankyo Company Information Table 76. Daiichi Sankyo Business Overview Table 77. Daiichi Sankyo Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Daiichi Sankyo Anticoagulants Product Portfolio Table 79. Daiichi Sankyo Recent Development Table 80. Otsuka Company Information Table 81. Otsuka Business Overview Table 82. Otsuka Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Otsuka Anticoagulants Product Portfolio Table 84. Otsuka Recent Development Table 85. AstraZeneca Company Information Table 86. AstraZeneca Business Overview Table 87. AstraZeneca Anticoagulants Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. AstraZeneca Anticoagulants Product Portfolio Table 89. AstraZeneca Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Anticoagulants Sales (kt), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 93. Pfizer Anticoagulants Product Portfolio Table 94. Pfizer Recent Development Table 95. Aspen Company Information Table 96. Aspen Business Overview Table 97. Aspen Anticoagulants Sales (kt), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 98. Aspen Anticoagulants Product Portfolio Table 99. Aspen Recent Development Table 100. The Medicines Company Company Information Table 101. The Medicines Company Business Overview Table 102. The Medicines Company Anticoagulants Sales (kt), Revenue (US$ Million), Price (USD/t) and Gross Margin (2021-2026) Table 103. The Medicines Company Anticoagulants Product Portfolio Table 104. The Medicines Company Recent Development Table 105. North America Anticoagulants Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Anticoagulants Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Anticoagulants Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Anticoagulants Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Anticoagulants Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Anticoagulants Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Anticoagulants Revenue by Country (US$ Million) & (2027-2032) Table 112. Europe Anticoagulants Revenue by Type (2021-2026) & (US$ Million) Table 113. Europe Anticoagulants Revenue by Type (2027-2032) & (US$ Million) Table 114. Europe Anticoagulants Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe Anticoagulants Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe Anticoagulants Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Anticoagulants Revenue by Country (2021-2026) & (US$ Million) Table 118. Europe Anticoagulants Revenue by Country (US$ Million) & (2027-2032) Table 119. China Anticoagulants Revenue by Type (2021-2026) & (US$ Million) Table 120. China Anticoagulants Revenue by Type (2027-2032) & (US$ Million) Table 121. China Anticoagulants Revenue by Application (2021-2026) & (US$ Million) Table 122. China Anticoagulants Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Anticoagulants Revenue by Type (2021-2026) & (US$ Million) Table 124. Asia Anticoagulants Revenue by Type (2027-2032) & (US$ Million) Table 125. Asia Anticoagulants Revenue by Application (2021-2026) & (US$ Million) Table 126. Asia Anticoagulants Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Anticoagulants Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Anticoagulants Revenue by Region (US$ Million) & (2021-2026) Table 129. Asia Anticoagulants Revenue by Region (US$ Million) & (2027-2032) Table 130. SAMEA Anticoagulants Revenue by Type (2021-2026) & (US$ Million) Table 131. SAMEA Anticoagulants Revenue by Type (2027-2032) & (US$ Million) Table 132. SAMEA Anticoagulants Revenue by Application (2021-2026) & (US$ Million) Table 133. SAMEA Anticoagulants Revenue by Application (2027-2032) & (US$ Million) Table 134. SAMEA Anticoagulants Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. SAMEA Anticoagulants Revenue by Country (2021-2026) & (US$ Million) Table 136. SAMEA Anticoagulants Revenue by Country (US$ Million) & (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Anticoagulants Image Figure 2. Global Anticoagulants Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anticoagulants Market Size Share 2021 VS 2025 VS 2032 Figure 4. Platelet Aggregation Inhibitors (PAI) Image Figure 5. Low-Molecular-Weight Heparin (LMWH) Image Figure 6. Direct Thrombin Inhibitor (DTI) Image Figure 7. Direct Factor Xa Inhibitors (DFXa) Image Figure 8. Vitamin K antagonists (VKA) Image Figure 9. Others Image Figure 10. Global Anticoagulants Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Anticoagulants Market Size Share 2021 VS 2025 VS 2032 Figure 12. VTE Image Figure 13. ACS/MI Image Figure 14. AF Image Figure 15. Others Image Figure 16. Global Anticoagulants Market Size (US$ Million) & (2021-2032) Figure 17. Global Anticoagulants Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Anticoagulants Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Anticoagulants Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Anticoagulants Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Anticoagulants Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Anticoagulants Revenue Market Share by Type (2021-2032) Figure 24. Global Anticoagulants Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Anticoagulants Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Anticoagulants Revenue Market Share by Application (2021-2032) Figure 27. North America Anticoagulants Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Anticoagulants Revenue Share by Type (2021-2032) Figure 29. North America Anticoagulants Revenue Share by Application (2021-2032) Figure 30. North America Anticoagulants Revenue Share by Country (2021-2032) Figure 31. United States Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Anticoagulants Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Anticoagulants Revenue Share by Type (2021-2032) Figure 36. Europe Anticoagulants Revenue Share by Application (2021-2032) Figure 37. Europe Anticoagulants Revenue Share by Country (2021-2032) Figure 38. Germany Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Anticoagulants Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Anticoagulants Revenue Share by Type (2021-2032) Figure 48. China Anticoagulants Revenue Share by Application (2021-2032) Figure 49. Asia Anticoagulants Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Anticoagulants Revenue Share by Type (2021-2032) Figure 51. Asia Anticoagulants Revenue Share by Application (2021-2032) Figure 52. Asia Anticoagulants Revenue Share by Region (2021-2032) Figure 53. Japan Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Anticoagulants Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Anticoagulants Revenue Share by Type (2021-2032) Figure 61. SAMEA Anticoagulants Revenue Share by Application (2021-2032) Figure 62. SAMEA Anticoagulants Revenue Share by Country (2021-2032) Figure 63. Brazil Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Anticoagulants Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Platelet Aggregation Inhibitors (PAI)
  • Low-Molecular-Weight Heparin (LMWH)
  • Direct Thrombin Inhibitor (DTI)
  • Direct Factor Xa Inhibitors (DFXa)
  • Vitamin K antagonists (VKA)
  • Others
Applications
  • VTE
  • ACS/MI
  • AF
  • Others
Companies covered
  • Sanofi
  • Bristol-Myers Squibb
  • Bayer
  • Johnson & Johnson.
  • Genentech (Roche)
  • Boehringer Ingelheim
  • Lilly
  • Daiichi Sankyo
  • Otsuka
  • AstraZeneca
  • Pfizer
  • Aspen
  • The Medicines Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anticoagulants Market by Type
  3. 1.2.1 Global Anticoagulants Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Platelet Aggregation Inhibitors (PAI)
  5. 1.2.3 Low-Molecular-Weight Heparin (LMWH)
  6. 1.2.4 Direct Thrombin Inhibitor (DTI)
  7. 1.2.5 Direct Factor Xa Inhibitors (DFXa)
  8. 1.2.6 Vitamin K antagonists (VKA)
  9. 1.2.7 Others
  10. 1.3 Anticoagulants Market by Application
  11. 1.3.1 Global Anticoagulants Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 VTE
  13. 1.3.3 ACS/MI
  14. 1.3.4 AF
  15. 1.3.5 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Anticoagulants Market Dynamics
  1. 2.1 Anticoagulants Industry Trends
  2. 2.2 Anticoagulants Industry Drivers
  3. 2.3 Anticoagulants Industry Opportunities and Challenges
  4. 2.4 Anticoagulants Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anticoagulants Market Perspective (2021-2032)
  2. 3.2 Global Anticoagulants Growth Trends by Region
  3. 3.2.1 Global Anticoagulants Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anticoagulants Market Size by Region (2021-2026)
  5. 3.2.3 Global Anticoagulants Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anticoagulants Revenue by Players
  2. 4.1.1 Global Anticoagulants Revenue by Players (2021-2026)
  3. 4.1.2 Global Anticoagulants Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anticoagulants Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anticoagulants Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anticoagulants Key Players Headquarters & Area Served
  7. 4.4 Global Anticoagulants Players, Product Type & Application
  8. 4.5 Global Anticoagulants Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anticoagulants Market CR5 and HHI
  11. 4.6.3 2025 Anticoagulants Tier 1, Tier 2, and Tier 3
5 Anticoagulants Market Size by Type
  1. 5.1 Global Anticoagulants Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anticoagulants Revenue by Type (2021-2032)
  3. 5.3 Global Anticoagulants Revenue Market Share by Type (2021-2032)
6 Anticoagulants Market Size by Application
  1. 6.1 Global Anticoagulants Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anticoagulants Revenue by Application (2021-2032)
  3. 6.3 Global Anticoagulants Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Anticoagulants Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Anticoagulants Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Bristol-Myers Squibb
  8. 7.2.1 Bristol-Myers Squibb Company Information
  9. 7.2.2 Bristol-Myers Squibb Business Overview
  10. 7.2.3 Bristol-Myers Squibb Anticoagulants Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myers Squibb Anticoagulants Product Portfolio
  12. 7.2.5 Bristol-Myers Squibb Recent Developments
  13. 7.3 Bayer
  14. 7.3.1 Bayer Company Information
  15. 7.3.2 Bayer Business Overview
  16. 7.3.3 Bayer Anticoagulants Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer Anticoagulants Product Portfolio
  18. 7.3.5 Bayer Recent Developments
  19. 7.4 Johnson & Johnson.
  20. 7.4.1 Johnson & Johnson. Company Information
  21. 7.4.2 Johnson & Johnson. Business Overview
  22. 7.4.3 Johnson & Johnson. Anticoagulants Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson. Anticoagulants Product Portfolio
  24. 7.4.5 Johnson & Johnson. Recent Developments
  25. 7.5 Genentech (Roche)
  26. 7.5.1 Genentech (Roche) Company Information
  27. 7.5.2 Genentech (Roche) Business Overview
  28. 7.5.3 Genentech (Roche) Anticoagulants Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Genentech (Roche) Anticoagulants Product Portfolio
  30. 7.5.5 Genentech (Roche) Recent Developments
  31. 7.6 Boehringer Ingelheim
  32. 7.6.1 Boehringer Ingelheim Company Information
  33. 7.6.2 Boehringer Ingelheim Business Overview
  34. 7.6.3 Boehringer Ingelheim Anticoagulants Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Boehringer Ingelheim Anticoagulants Product Portfolio
  36. 7.6.5 Boehringer Ingelheim Recent Developments
  37. 7.7 Lilly
  38. 7.7.1 Lilly Company Information
  39. 7.7.2 Lilly Business Overview
  40. 7.7.3 Lilly Anticoagulants Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Lilly Anticoagulants Product Portfolio
  42. 7.7.5 Lilly Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Anticoagulants Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Anticoagulants Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 Otsuka
  50. 7.9.1 Otsuka Company Information
  51. 7.9.2 Otsuka Business Overview
  52. 7.9.3 Otsuka Anticoagulants Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Otsuka Anticoagulants Product Portfolio
  54. 7.9.5 Otsuka Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Anticoagulants Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Anticoagulants Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Anticoagulants Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Anticoagulants Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Aspen
  68. 7.12.1 Aspen Company Information
  69. 7.12.2 Aspen Business Overview
  70. 7.12.3 Aspen Anticoagulants Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Aspen Anticoagulants Product Portfolio
  72. 7.12.5 Aspen Recent Developments
  73. 7.13 The Medicines Company
  74. 7.13.1 The Medicines Company Company Information
  75. 7.13.2 The Medicines Company Business Overview
  76. 7.13.3 The Medicines Company Anticoagulants Revenue and Gross Margin (2021-2026)
  77. 7.13.4 The Medicines Company Anticoagulants Product Portfolio
  78. 7.13.5 The Medicines Company Recent Developments
8 North America
  1. 8.1 North America Anticoagulants Revenue (2021-2032)
  2. 8.2 North America Anticoagulants Revenue by Type (2021-2032)
  3. 8.2.1 North America Anticoagulants Revenue by Type (2021-2026)
  4. 8.2.2 North America Anticoagulants Revenue by Type (2027-2032)
  5. 8.3 North America Anticoagulants Revenue Share by Type (2021-2032)
  6. 8.4 North America Anticoagulants Revenue by Application (2021-2032)
  7. 8.4.1 North America Anticoagulants Revenue by Application (2021-2026)
  8. 8.4.2 North America Anticoagulants Revenue by Application (2027-2032)
  9. 8.5 North America Anticoagulants Revenue Share by Application (2021-2032)
  10. 8.6 North America Anticoagulants Revenue by Country
  11. 8.6.1 North America Anticoagulants Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anticoagulants Revenue by Country (2021-2026)
  13. 8.6.3 North America Anticoagulants Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Anticoagulants Revenue (2021-2032)
  2. 9.2 Europe Anticoagulants Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anticoagulants Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anticoagulants Revenue by Type (2027-2032)
  5. 9.3 Europe Anticoagulants Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anticoagulants Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anticoagulants Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anticoagulants Revenue by Application (2027-2032)
  9. 9.5 Europe Anticoagulants Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anticoagulants Revenue by Country
  11. 9.6.1 Europe Anticoagulants Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anticoagulants Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anticoagulants Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Anticoagulants Revenue (2021-2032)
  2. 10.2 China Anticoagulants Revenue by Type (2021-2032)
  3. 10.2.1 China Anticoagulants Revenue by Type (2021-2026)
  4. 10.2.2 China Anticoagulants Revenue by Type (2027-2032)
  5. 10.3 China Anticoagulants Revenue Share by Type (2021-2032)
  6. 10.4 China Anticoagulants Revenue by Application (2021-2032)
  7. 10.4.1 China Anticoagulants Revenue by Application (2021-2026)
  8. 10.4.2 China Anticoagulants Revenue by Application (2027-2032)
  9. 10.5 China Anticoagulants Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anticoagulants Revenue (2021-2032)
  2. 11.2 Asia Anticoagulants Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anticoagulants Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anticoagulants Revenue by Type (2027-2032)
  5. 11.3 Asia Anticoagulants Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anticoagulants Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anticoagulants Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anticoagulants Revenue by Application (2027-2032)
  9. 11.5 Asia Anticoagulants Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anticoagulants Revenue by Country
  11. 11.6.1 Asia Anticoagulants Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anticoagulants Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anticoagulants Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anticoagulants Revenue (2021-2032)
  2. 12.2 SAMEA Anticoagulants Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anticoagulants Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anticoagulants Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anticoagulants Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anticoagulants Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anticoagulants Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anticoagulants Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anticoagulants Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anticoagulants Revenue by Country
  11. 12.6.1 SAMEA Anticoagulants Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anticoagulants Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anticoagulants Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst